Global Non-Tumorous Skin Diseases Therapeutics Market 2020-2024 | Evolving Opportunities with AbbVie Inc. and Amgen Inc. | Technavio

Technavio has announced its latest market research report titled global non-tumorous skin diseases therapeutics market 2020-2024 (Graphic: Business Wire)

LONDON--()--Technavio has been monitoring the global non-tumorous skin diseases therapeutics market since 2019, and the market is poised to grow by USD 12.93 billion during 2020-2024, progressing at a CAGR of more than 9% during the forecast period. Request free sample pages

Read the 157-page report with TOC on “Non-Tumorous Skin Diseases Therapeutics Market Analysis Report by Application (psoriasis, eczema, acne vulgaris, and other applications), Geography (Asia, Europe, North America, and ROW), and the Segment Forecasts, 2020-2024”.

https://www.technavio.com/report/non-tumorous-skin-diseases-therapeutics-market-industry-analysis

The high prevalence of skin diseases drives the market and increasing healthcare expenditure is anticipated to boost the growth of the non-tumorous skin diseases therapeutics market.

Factors such as microorganisms living on the skin, compromised immune system, genetic factors, and exposure to irritants, allergens, or another person’s infected skin have increased the prevalence of skin diseases across the world. According to estimates, nearly 125 million people across the world are currently affected by psoriasis, of which over 8 million cases are from the US. Also, the prevalence of other skin conditions such as atopic dermatitis and rosacea is increasing across the world. This is increasing the number of patient visits to dermatologists and the demand for numerous medications. These factors are fueling the growth of the global non-tumorous skin diseases therapeutics market.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Non-Tumorous Skin Diseases Therapeutics Market Companies:

AbbVie Inc.

AbbVie Inc. operates the business through the Pharmaceuticals segment. HUMIRA is the key offering of the company. It is a TNF inhibitor used for the treatment of chronic plaque psoriasis, rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, juvenile idiopathic arthritis, and uveitis.

Amgen Inc.

Amgen Inc. operates the business through the human therapeutics segment. The company offers a wide range of non-tumorous skin diseases therapeutics. ENBREL and Otezla are some of the key offerings of the company.

Bausch Health Companies, Inc.

Bausch Health Companies Inc. operates the business across segments such as Bausch + Lomb/International, Salix, Diversified Products, and Ortho Dermatologics. The company offers a wide range of non-tumorous skin diseases therapeutics. SILIQ and ONEXTON are some of the key offerings of the company.

Eli Lilly and Co.

Eli Lilly and Co. operates the business across segments such as human pharmaceutical products and animal health products. Taltz -. a biologic injection used for the treatment of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis - is the key offering of the company.

Galderma Laboratories LP

Galderma Laboratories LP operates the business through the Medical solutions segment. The company offers a wide range of non-tumorous skin diseases therapeutics. Some of the key offerings include AKLIEF, MIRVASO, SOOLANTRA, and ORACEA.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Non-Tumorous Skin Diseases Therapeutics Application Outlook (Revenue, USD Billion, 2020 - 2024)

  • Psoriasis
  • Eczema
  • Acne vulgaris
  • Other applications

Non-Tumorous Skin Diseases Therapeutics Regional Outlook (Revenue, USD Billion, 2020 - 2024)

  • Asia
  • Europe
  • North America
  • ROW

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Healthcare are:

Global Eczema Therapeutics Market – Global eczema therapeutics market by geography (Asia, Europe, North America, and ROW) and indication (atopic dermatitis, contact dermatitis, and other indication).

Global Seborrheic Keratosis Treatment Market – Global seborrheic keratosis treatment market by type (cryotherapy, electrocautery, and other treatments) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Release Summary

The global non-tumorous skin diseases therapeutics market is poised to grow by USD 12.93 billion during 2020-2024.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com